MDXG - MiMedx Group Inc logo

MiMedx Group Inc

MDXG

MiMedx Group develops and distributes placental tissue allografts for wound care and surgical applications, utilizing its PURION process to maintain biological properties. It sells products like EPIFIX and AMNIOFIX through a direct sales force and distributors.

βš•οΈ Healthcare NASDAQ Listed 2007 $ USD
$1,000 invested 10 years ago β†’$463today

Score Overview

1 Year
Score
Net Growth-87.16%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth-15.16%
Rev TrendShrank
Revenue Consistencyβ€”
5 Years
Score6.0
Net Growth150.70%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth46.75%
Rev Trend80%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-47.91%
Net Trend40%
Net Income Consistency
Rev Growth44.96%
Rev Trend60%
Revenue Consistency
All Time
Scoreβ€”
Net Growthβ€”
Net Trend61%
Net Income Consistency
Rev Growthβ€”
Rev Trend75%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where MiMedx Group Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by Net Income Growth.

Has not reached the top 50 on Net Income Growth in any year we have ranked.

  • MDXG

2019: 83.9% Β· 2021: 87.6% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 3.93β€”
1 Year2025-10-22
$ 6.72-41.52%
5 Years2021-10-22
$ 7.03-44.10%
10 Years2016-10-21
$ 8.48-53.66%
All Time2007-08-22
$ 0.1039x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 355M$ 6M$ 135M
2025$ 418M$ 48M$ 166M
2024$ 348M$ 42M$ 104M
2023$ 321M$ 67M$ 82M
2022$ 267M-$ 30M$ 65M
2021$ 242M-$ 12M$ 87M
2020$ 248M-$ 49M$ 95M
2019$ 359M-$ 29M$ 45M
2018$ 359M-$ 29M$ 45M
2017$ 321M$ 64M$ 27M
2016$ 245M$ 11M$ 34M
2015$ 187M$ 29M$ 31M
2014$ 118M$ 6M$ 52M
2013$ 59M-$ 4M$ 44M
2012$ 27M-$ 7M$ 6M
2011$ 7M-$ 10M$ 4M
2010$ 788.87K-$ 11M$ 1M
2009-$ 11M$ 2M
2008-$ 17M$ 6M
IPO2007$ 184.00
MDXG - MiMedx Group Inc logo

MiMedx Group Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 248M to $ 418M and net income went from -$ 49M to $ 48M. Revenue increased in 4 of those 5 years; net income in 2.

Between 2015 and 2025, revenue grew from $ 187M to $ 418M and net income grew from $ 29M to $ 48M. Revenue increased in 6 of those 10 years; net income in 4.

MiMedx Group Inc currently holds a 5-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.

Membership

Continue MDXG’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies